Compare Stocks: SPRO, ACB, ZNTL, and CRDL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACB Aurora Cannabis	$3.87 +0.5%	$3.39	$2.56 ▼ $6.66	$250.94M	0.63	972,211 shs	622,454 shs
CRDL Cardiol Therapeutics	$1.88 +0.8%	$1.66	$0.88 ▼ $2.34	$217.83M	0.79	1.50 million shs	972,938 shs
SPRO Spero Therapeutics	$1.13 +0.9%	$1.26	$1.08 ▼ $3.08	$65.81M	1.49	327,356 shs	501,370 shs
ZNTL Zentalis Pharmaceuticals	$3.11 +1.0%	$4.14	$1.21 ▼ $6.95	$222.90M	1.85	812,555 shs	1.26 million shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACB Aurora Cannabis	0.00%	+3.48%	+1.57%	+32.08%	-22.44%
CRDL Cardiol Therapeutics	0.00%	-6.02%	-0.53%	+76.89%	+73.61%
SPRO Spero Therapeutics	0.00%	0.00%	-6.61%	-50.44%	-40.53%
ZNTL Zentalis Pharmaceuticals	0.00%	-11.40%	-19.01%	-15.95%	+119.01%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACB Aurora Cannabis	$3.87 +0.5%	$3.39	$2.56 ▼ $6.66	$250.94M	0.63	972,211 shs	622,454 shs
CRDL Cardiol Therapeutics	$1.88 +0.8%	$1.66	$0.88 ▼ $2.34	$217.83M	0.79	1.50 million shs	972,938 shs
SPRO Spero Therapeutics	$1.13 +0.9%	$1.26	$1.08 ▼ $3.08	$65.81M	1.49	327,356 shs	501,370 shs
ZNTL Zentalis Pharmaceuticals	$3.11 +1.0%	$4.14	$1.21 ▼ $6.95	$222.90M	1.85	812,555 shs	1.26 million shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACB Aurora Cannabis	0.00%	+3.48%	+1.57%	+32.08%	-22.44%
CRDL Cardiol Therapeutics	0.00%	-6.02%	-0.53%	+76.89%	+73.61%
SPRO Spero Therapeutics	0.00%	0.00%	-6.61%	-50.44%	-40.53%
ZNTL Zentalis Pharmaceuticals	0.00%	-11.40%	-19.01%	-15.95%	+119.01%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACB Aurora Cannabis	2.50	Moderate Buy	N/A	N/A
CRDL Cardiol Therapeutics	2.50	Moderate Buy	$10.00	433.33% Upside
SPRO Spero Therapeutics	2.25	Hold	$6.00	430.97% Upside
ZNTL Zentalis Pharmaceuticals	2.40	Hold	$6.75	117.04% Upside

Current Analyst Ratings Breakdown

Latest SPRO, ACB, ZNTL, and CRDL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/16/2026	ACB Aurora Cannabis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/16/2026	ZNTL Zentalis Pharmaceuticals	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform
9/14/2026	SPRO Spero Therapeutics	Compass Point Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral
9/14/2026	SPRO Spero Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
9/14/2026	SPRO Spero Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$5.00 ➝ $6.00
8/26/2026	ACB Aurora Cannabis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/26/2026	CRDL Cardiol Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$11.00
8/17/2026	CRDL Cardiol Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$8.00 ➝ $10.00
8/12/2026	SPRO Spero Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Hold (C-)
8/11/2026	ACB Aurora Cannabis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D) ➝ Sell (E+)
8/7/2026	ACB Aurora Cannabis	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy

(Data available from 9/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACB Aurora Cannabis	$247.82M	1.01	$0.70 per share	5.51	$6.27 per share	0.62
CRDL Cardiol Therapeutics	N/A	N/A	N/A	N/A	$0.11 per share	N/A
SPRO Spero Therapeutics	$66.80M	0.99	$0.15 per share	7.43	$1.05 per share	1.08
ZNTL Zentalis Pharmaceuticals	$67.43M	3.31	N/A	N/A	$2.99 per share	1.04

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACB Aurora Cannabis	-$88.13M	-$1.41	N/A	64.50	N/A	-32.26%	4.37%	3.45%	11/4/2026 (Estimated)
CRDL Cardiol Therapeutics	-$24.20M	-$0.25	N/A	N/A	N/A	N/A	-180.44%	-140.28%	11/12/2026 (Estimated)
SPRO Spero Therapeutics	$8.57M	$0.11	10.27	N/A	N/A	24.90%	16.17%	12.57%	11/12/2026 (Estimated)
ZNTL Zentalis Pharmaceuticals	-$137.06M	-$1.95	N/A	N/A	N/A	N/A	-70.18%	-51.46%	11/10/2026 (Estimated)

Latest SPRO, ACB, ZNTL, and CRDL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	CRDL Cardiol Therapeutics	-$0.09	-$0.04	+$0.05	-$0.04	N/A	N/A
8/12/2026	Q2 2026	SPRO Spero Therapeutics	-$0.17	-$0.16	+$0.01	-$0.16	N/A	N/A
8/6/2026	Q2 2026	ZNTL Zentalis Pharmaceuticals	-$0.49	-$0.59	-$0.10	-$0.59	N/A	N/A
8/5/2026	Q1 2027	ACB Aurora Cannabis	-$0.13	$0.04	+$0.17	-$0.05	$47.45 million	$47.62 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACB Aurora Cannabis	N/A	N/A	N/A	N/A	N/A
CRDL Cardiol Therapeutics	N/A	N/A	N/A	N/A	N/A
SPRO Spero Therapeutics	N/A	N/A	N/A	N/A	N/A
ZNTL Zentalis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACB Aurora Cannabis	0.03	5.36	2.80
CRDL Cardiol Therapeutics	N/A	5.55	5.55
SPRO Spero Therapeutics	N/A	6.12	6.12
ZNTL Zentalis Pharmaceuticals	N/A	4.82	4.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACB Aurora Cannabis	47.63%
CRDL Cardiol Therapeutics	12.49%
SPRO Spero Therapeutics	25.60%
ZNTL Zentalis Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
ACB Aurora Cannabis	0.01%
CRDL Cardiol Therapeutics	5.25%
SPRO Spero Therapeutics	2.90%
ZNTL Zentalis Pharmaceuticals	3.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACB Aurora Cannabis	1,028	64.84 million	64.84 million	Optionable
CRDL Cardiol Therapeutics	18	116.18 million	110.08 million	Not Optionable
SPRO Spero Therapeutics	150	58.24 million	56.55 million	Optionable
ZNTL Zentalis Pharmaceuticals	106	71.67 million	68.95 million	Optionable

SPRO, ACB, ZNTL, and CRDL Headlines

Recent News About These Companies

Zentalis Pharmaceuticals stock falls after public offering pricing and trades below recent highs

September 18 at 5:55 PM | ad-hoc-news.deA

William Blair Initiates Coverage on Zentalis Pharmaceuticals (NASDAQ:ZNTL)

September 16, 2026 | marketbeat.com

Comparing Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Sol-Gel Technologies (NASDAQ:SLGL)

September 16, 2026 | americanbankingnews.com

William Blair Starts Zentalis Pharmaceuticals (ZNTL) at Outperform

September 16, 2026 | streetinsider.com

Zentalis Pharmaceuticals, Inc. (ZNTL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 14, 2026 | seekingalpha.com

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Rating of "Hold" by Brokerages

September 10, 2026 | americanbankingnews.com

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Consensus Rating of "Hold" by Analysts

September 10, 2026 | marketbeat.com

BlackRock Inc. Invests $18.20 Million in Zentalis Pharmaceuticals, Inc. $ZNTL

September 4, 2026 | marketbeat.com

Zentalis to present at Wells Fargo, Morgan Stanley events

September 2, 2026 | msn.com

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

September 2, 2026 | globenewswire.com

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 1, 2026 | globenewswire.com

Zentalis Pharmaceuticals: Data Due H1 '27 Will Clarify Prospects Of Azenosertib

August 31, 2026 | seekingalpha.com

Connor Clark & Lunn Investment Management Ltd. Makes New Investment in Zentalis Pharmaceuticals, Inc. $ZNTL

August 29, 2026 | marketbeat.com

Primecap Management Co. CA Takes $4.64 Million Position in Zentalis Pharmaceuticals, Inc. $ZNTL

August 27, 2026 | marketbeat.com

652,750 Shares in Zentalis Pharmaceuticals, Inc. $ZNTL Acquired by ADAR1 Capital Management LLC

August 26, 2026 | marketbeat.com

3,947,913 Shares in Zentalis Pharmaceuticals, Inc. $ZNTL Acquired by 5AM Venture Management LLC

August 26, 2026 | marketbeat.com

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Major Shareholder Group Walters Acquires 4,335,000 Shares

August 20, 2026 | insidertrades.com

Zentalis Pharma closes $92.6 million public offering

August 19, 2026 | thepharmaletter.comT

Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

August 17, 2026 | markets.businessinsider.com

Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

August 17, 2026 | globenewswire.com

Zentalis Pharmaceuticals Prices $80.5 Million Offering to Fund Clinical Pipeline

August 14, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

SPRO, ACB, ZNTL, and CRDL Company Descriptions

Aurora Cannabis NASDAQ:ACB

$3.87 +0.02 (+0.52%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$3.90 +0.03 (+0.75%)

As of 09/18/2026 07:59 PM Eastern

Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, the Caribbean, South America, and Israel; supply of propagated vegetables and ornamental plants in North America; and distribution and sale of hemp-derived cannabidiol (CBD) products. In addition, the company cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, edibles, and extracts; and provides dried flowers, vapes, dried milled strains, strain-specific extracts, strain specific cannabis oils, and concentrates. Further, it offers recreational cannabis products, such as flowers, vapes, ingestibles, concentrates, extracts, and CBD products; and patient counseling and outreach services. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.

Cardiol Therapeutics NASDAQ:CRDL

$1.88 +0.02 (+0.81%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$1.93 +0.05 (+2.72%)

As of 09/18/2026 07:30 PM Eastern

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.

Spero Therapeutics NASDAQ:SPRO

$1.13 +0.01 (+0.89%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$1.12 0.00 (-0.44%)

As of 09/18/2026 07:30 PM Eastern

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Zentalis Pharmaceuticals NASDAQ:ZNTL

$3.11 +0.03 (+0.97%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$3.18 +0.07 (+2.35%)

As of 09/18/2026 07:55 PM Eastern

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SPRO, ACB, ZNTL, and CRDL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SPRO, ACB, ZNTL, and CRDL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SPRO, ACB, ZNTL, and CRDL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

SPRO, ACB, ZNTL, and CRDL Company Descriptions

Aurora Cannabis NASDAQ:ACB

Cardiol Therapeutics NASDAQ:CRDL

Spero Therapeutics NASDAQ:SPRO

Zentalis Pharmaceuticals NASDAQ:ZNTL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SPRO, ACB, ZNTL, and CRDL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SPRO, ACB, ZNTL, and CRDL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SPRO, ACB, ZNTL, and CRDL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

SPRO, ACB, ZNTL, and CRDL Company Descriptions

Aurora Cannabis NASDAQ:ACB

Cardiol Therapeutics NASDAQ:CRDL

Spero Therapeutics NASDAQ:SPRO

Zentalis Pharmaceuticals NASDAQ:ZNTL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools